Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Monoclonal antibodies targeting novel sites of vulnerability in marburg virus glycoprotein

Award Number: R41AI147929
ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 07/12/2019
PERIOD OF PERFORMANCE END DATE: 10/30/2022

Group Awards By:

View Award Description

Monoclonal antibodies targeting novel sites of vulnerability in marburg virus glycoprotein - Filoviruses, consisting of two major virus families including the ebolaviruses and marburgviruses (MARV and RAVV), cause periodic outbreaks of severe viral hemorrhagic fever with mortality rates as high as 90%. Since it is difficult to predict the species that would dominate future outbreaks, development of broadly protective therapeutics to prevent and manage future filovirus outbreaks is of high priority. In sharp contrast to the recent major breakthrough reported by us and others on isolation and development of a number of effective and broadly neutralizing mAbs (bNAbs) for ebolaviruses, only a single class of mAbs against marburgvirus GP has been described that target the same epitope within the receptor binding site (RBS) of MARV and RAVV GP. MR191 is the only MARV/RAVV GP RBS-specific monoclonal antibody (mAb) that has been shown to protect against MARV infection in nonhuman primates (NHPs) however at very high doses (2 doses of 50 mg/kg each). Thus, it is important to identify novel sites of vulnerability in MARV/RAVV GP and develop more potent immunotherapeutics against these deadly viruses. Having a variety of bNAbs will allow the design of therapeutic cocktails containing multiple mAbs targeting distinct epitopes, a strategy that has been shown tobe extremely effective against ebolaviruses to combat possible virus escape variants. There has been a long-standing and productive collaboration between Integrated BioTherapeutics (IBT) and University of Maryland (UMD) that has recently resulted in highly potent ebolavirus bNAbs with remarkable efficacy in animal models including nonhuman primate (NHP) and ferret models of EBOV, SUDV, and BDBV infection (Zhao et al., Cell 169, 891-904 e815 (2017)). Lately, using a prime/boost immunization strategy in NHPs combined with a novel memory B cell counter-screening with engineered GP mutants, we were able to isolate, for the first time, a group of highly potent MARV/RAVV bNAbs that target a new class of epitopes distinct from the RBS-binding MR series. In this STTR application, we aim to address the major challenge of MARV immunotherapy by developing top lead candidate marburgvirus therapeutic antibodies derived from these novel MARV/RAVV bNAbs. We will i) select 3-4 lead therapeutic mAbs among the current bNAb candidates; ii) optimize the lead mAbs and select for the final humanized/optimized candidate by state-of-the-art computer-aided optimization and efficacy study in a stringent guinea pig model of MARV infection; and iii) identify the final lead mAb (or cocktail) by testing the efficacy of candidates in NHP model of MARV infection. Upon completion of the proposed Phase I project we envision a Phase II project with the following objectives: i) expand the efficacy studies to RAVV and dose optimization in NHPs; ii) develop manufacturing cell lines in CHO cells, iii) develop bioanalytical methods for product release and PK, and iv) conduct safety and tissue cross reactivity studies using the GLP-grade clinical candidate. If successful, we anticipate further development of the product under DoD or BARDA funding and approval under FDA Animal Rule.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2024 ( Subtotal = $0 )
2024	2020	INTEGRATED BIOTHERAPEUTICS, LLC	4 RESEARCH CT STE 300	ROCKVILLE	MD	20850	MONTGOMERY	USA	Allergy and Infectious Diseases Research	000	2	10/18/2023	NON-COMPETING CONTINUATION	$0
														Subtotal = $0

Issue Date FY: 2022 ( Subtotal = $0 )
2022	2020	INTEGRATED BIOTHERAPEUTICS INC	4 RESEARCH CT	POTOMAC	MD	20850	MONTGOMERY	USA	Allergy and Infectious Diseases Research	000	2	6/2/2022	NON-COMPETING CONTINUATION	$0
														Subtotal = $0

Issue Date FY: 2020 ( Subtotal = $300,000 )
2020	2020	INTEGRATED BIOTHERAPEUTICS, INC.	4 RESEARCH COURT, SUITE 300	ROCKVILLE	MD	20850	MONTGOMERY	USA	Allergy and Infectious Diseases Research	000	2	6/9/2020	NON-COMPETING CONTINUATION	$300,000
														Subtotal = $300,000

Issue Date FY: 2019 ( Subtotal = $300,000 )
2019	2019	INTEGRATED BIOTHERAPEUTICS, INC.	4 RESEARCH COURT, SUITE 300	ROCKVILLE	MD	20850	MONTGOMERY	USA	Allergy and Infectious Diseases Research	000	1	7/12/2019	NEW	$300,000
														Subtotal = $300,000

Grand Total All Awards = $600,000

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Monoclonal antibodies targeting novel sites of vulnerability in marburg virus glycoprotein

Award Number: R41AI147929

ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 07/12/2019

PERIOD OF PERFORMANCE END DATE: 10/30/2022

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer